BTG touts Ekos data from pulmonary embolism trial

BTG (LON:BTG) touted data today from the Optalyse PE trial showing that pulmonary embolism can be treated effectively with Ekos over a shorter period and with smaller doses of thrombolytic drugs compared to the current standard. The 101-patient trial randomized participants to receive therapeutic anticoagulation and Ekos acoustic pulse thrombolysis therapy at different doses for different lengths of time. The 1st group received 4 milligrams per catheter of tissue plasminogen activator over 2 hours, while the 2nd cohort received the same dose over 4 hours. The 3rd group was treated with 6 milligrams per catheter over 6 hours and the 4th group received 12 milligrams per catheter over 6 hours. BTG’s Ekos system uses ultrasonic waves in combination with thrombolytic drugs to dissolve clots and restore heart function. Get the full story at our sister site, Drug Delivery Business News. The post BTG touts Ekos data from pulmonary embolism trial appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Cardiovascular Clinical Trials Drug-Device Combinations Wall Street Beat BTG Source Type: news